SIGHT SCIENCES INC. - COMMON STOCK

Sight Sciences to Host SAHARA 6 Month RCT Results Reception at the American Academy of Ophthalmology 2023

19 Oct 2023 16:05:00 By Nasdaq GlobeNewswire

Sight Sciences Announces Presentation of Successful Phase I Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease at the American Academy of Optometry Annual Meeting

12 Oct 2023 16:05:00 By Nasdaq GlobeNewswire

Sight Sciences Announces New, Large-Scale MIGS Data from 41st Congress of ESCRS Demonstrating TCOR™ Using OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma

03 Oct 2023 08:30:00 By Nasdaq GlobeNewswire

Sight Sciences Provides Revenue Guidance for the Third Quarter of 2023 and Updates Revenue Guidance for Full Year 2023

11 Sep 2023 16:06:00 By Nasdaq GlobeNewswire

Sight Sciences Appoints Matt Link as Chief Commercial Officer

11 Sep 2023 16:05:00 By Nasdaq GlobeNewswire

Sight Sciences to Present at the Upcoming Morgan Stanley 21st Annual Global Healthcare Conference

30 Aug 2023 16:05:00 By Nasdaq GlobeNewswire

Sight Sciences Reports Second Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023

03 Aug 2023 16:05:01 By Nasdaq GlobeNewswire

Sight Sciences to Report Second Quarter 2023 Financial Results on August 3, 2023

20 Jul 2023 16:05:00 By Nasdaq GlobeNewswire

Sight Sciences Announces Positive Results and Primary Endpoint Successfully Met in SAHARA, a Randomized Controlled Clinical Trial Comparing Interventional Eyelid Procedures Enabled by TearCare® Technology to Restasis¹ for the Treatment of Dry Eye

20 Jul 2023 08:30:00 By Nasdaq GlobeNewswire

Cigna Expands Coverage of Glaucoma Surgical Procedures to Include Canaloplasty and Goniotomy (Trabeculotomy)

21 Jun 2023 08:30:00 By Nasdaq GlobeNewswire

Sight Sciences Announces Addition of New Director Catherine Mazzacco

09 Jun 2023 16:05:00 By Nasdaq GlobeNewswire

Sight Sciences Two Year Multicenter Study Results Show Sustained Reductions in Both Intraocular Pressure (IOP) and Glaucoma Medication Use in Mild-Moderate Primary Open Angle Glaucoma Patients Treated with a Procedure Enabled with the OMNI® Surgical System Technology

23 May 2023 08:30:01 By Nasdaq GlobeNewswire

Sight Sciences Announces 12-month Results from the First Minimally Invasive Glaucoma Surgery (MIGS) Comparative Analysis of Real-World Data (RWD) from the American Academy of Ophthalmology IRIS® Registry

06 May 2023 11:30:00 By Nasdaq GlobeNewswire

Sight Sciences Reports First Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023

04 May 2023 16:05:01 By Nasdaq GlobeNewswire

Sight Sciences' Glaucoma and Dry Eye Technologies to be Featured in Multiple Clinical Presentations at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

01 May 2023 16:05:00 By Nasdaq GlobeNewswire

Sight Sciences to Present at the Upcoming Bank of America Securities 2023 Health Care Conference

26 Apr 2023 16:05:01 By Nasdaq GlobeNewswire

Sight Sciences to Report First Quarter 2023 Financial Results on May 4, 2023

20 Apr 2023 16:05:00 By Nasdaq GlobeNewswire

Sight Sciences to Host Surgical Glaucoma Investor Symposium on Friday, May 5, 2023

13 Apr 2023 16:05:41 By Nasdaq GlobeNewswire

Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer

03 Apr 2023 16:05:00 By Nasdaq GlobeNewswire

Sight Sciences Defeats Invalidity Challenges Filed By Alcon and Ivantis In The U.S. Patent Office

30 Mar 2023 08:00:00 By Nasdaq GlobeNewswire